arrow
D

David M. Burger

Radboud University Medical Center
H指数:66
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial

加速适用于4周龄以上艾滋病儿童的单一片剂型多替拉韦–恩曲他滨–替诺福韦艾拉酚胺固定剂量比一线方案的推广应用:一项为期24周、开放标签、单臂、Ⅰ–Ⅱ期、药代动力学、安全性和抗病毒活性试验

2026-09-070
PRE
Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment

HIV感染者婴儿中阿巴卡韦和拉米夫定的药代动力学研究(联合或不联合利福平治疗)

2026-08-200
OAAI
Ribavirin post-exposure prophylaxis for Andes virus exposure: a viewpoint

利巴韦林暴露后预防用于安第斯病毒暴露:一种观点

2026-07-160
OAAI
The Effects on the Growth of HIV-exposed Uninfected Infants of Initiating Dolutegravir-based Versus Efavirenz-based cART in Late Pregnancy (DolPHIN-2)

妊娠晚期 (DolPHIN-2) 启动基于Dolutegravir和基于Efavirenz的cART对HIV暴露的未感染婴儿生长的影响

2025-11-010
PRE
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial

每日一次的达芦那韦/拉米夫定固定剂量制剂在HIV感染者儿童中的应用:一项在开放标签、多中心、随机、非劣效性D3/PENTA 21试验中嵌套的药代动力学和安全性的子研究

2025-09-260
PREAI
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patients
2024-09-030
OA
Plasma concentrations of first line antituberculosis drugs in infants with HIV and severe pneumonia: a pharmacokinetic sub-study of the empirical trial
2023-12-170
OA